bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

BLUE anticipates multibillion-dollar revenue opportunities in gene therapy

BLUE's Q2 performance reflects solid product revenue and a strong cash position. The company is navigating challenges in the treatment process and restricted cash issues while strategically planning for the commercial launch of lovo-cel, which presents significant revenue opportunities.

BLUE anticipates FDA approval for lovo-cel, reports $12.4M revenue

BLUE's Q3 earnings call highlighted the potential FDA approval of lovo-cel, progress in ZYNTEGLO and SKYSONA launches, and financial insights including revenue and cash runway. The company faces manufacturing and safety challenges but sees opportunities in expanding its QTC network and pricing strategies for lovo-cel.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

NEW YORK , April 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE). Shareholders who purchased shares of BLUE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

BLUE LAWSUIT ALERT: The Gross Law Firm Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / April 25, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=77087&wire=1 or contact Joseph E. Levi, Esq.

May 28, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BLUE

NEW YORK, NY / ACCESSWIRE / April 25, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=77085&wire=1 or contact Joseph E. Levi, Esq.

bluebird bio, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights – BLUE

NEW YORK, NY / ACCESSWIRE / April 25, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=77086&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) Shareholders

NEW YORK, NY / ACCESSWIRE / April 25, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=77051&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio Lawsuit – BLUE

LOS ANGELES, CA / ACCESSWIRE / April 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("bluebird" or "the Company") (NASDAQ:BLUE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 24, 2023 and December 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before May 28, 2024.

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / April 25, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76998&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc.(BLUE) Shareholders

NEW YORK, NY / ACCESSWIRE / April 25, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=77005&wire=1 or contact Joseph E. Levi, Esq.

bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BLUE

NEW YORK , April 25, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against bluebird bio, Inc. ("Blue" or the "Company") (NASDAQ: BLUE) and reminds investors of the May 28, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Blue To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Blue stock or options between April 24, 2023 and December 8, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Blue

NEW YORK, NY / ACCESSWIRE / April 25, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76990&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BLUE

NEW YORK, NY / ACCESSWIRE / April 25, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76986&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESSWIRE / April 25, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76973&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by May 28, 2024 Deadline to Join Class Action Against bluebird bio, Inc.(BLUE)

Apple

AbbVie

AGNC Investment

Antero Midstream Partners

Apple Hospitality REIT

Ares Capital

Apollo Commercial Real Estate Finance

Broadcom

Boeing

Alibaba

Bank of America

BASF SE

Brookfield Renewable Partners

B&G Foods

Bank of Montreal

Bayerische Motoren Werke AG

Bank of Nova Scotia

BRT Apartments

Blackstone Group

Blackstone Secured Lending Fund

Colgate-Palmolive

Global stock indices continued an upward trend in March, with both U.S. and non-U.S. stocks rising by 3%.

March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys

NEW YORK, NY / ACCESSWIRE / April 24, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76900&wire=1 or contact Joseph E. Levi, Esq.

bluebird bio, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights - BLUE

NEW YORK, NY / ACCESSWIRE / April 24, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76899&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against bluebird bio, Inc. (BLUE) Seeking Recovery for Investors - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / April 24, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76883&wire=1 or contact Joseph E. Levi, Esq.

bluebird bio, Inc. Class Action: Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024 – BLUE

NEW YORK, NY / ACCESSWIRE / April 24, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76880&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on bluebird bio, Inc. (BLUE)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / April 24, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76868&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against bluebird bio, Inc. (BLUE) - May 28, 2024 Deadline to Join - Contact Levi & Korsinsky

BENSALEM, Pa. , April 24, 2024 /PRNewswire/ -- Law Offices of Howard G.

BLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud Lawsuit

NEW YORK, NY / ACCESSWIRE / April 24, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76848&wire=1 or contact Joseph E. Levi, Esq.

Investors in bluebird bio, Inc. Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights - BLUE

NEW YORK, NY / ACCESSWIRE / April 24, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76783&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024 - BLUE

NEW YORK, NY / ACCESSWIRE / April 23, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76745&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against bluebird bio, Inc. (BLUE) Seeking Recovery for Investors – Contact Levi & Korsinsky

LOS ANGELES , April 23, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("bluebird" or "the Company") (NASDAQ: BLUE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 24, 2023 and December 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before May 28, 2024.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / April 22, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76599&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio Lawsuit - BLUE

NEW YORK, NY / ACCESSWIRE / April 22, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76531&wire=1 or contact Joseph E. Levi, Esq.

News for bluebird bio Stock (BLUE)